Applying pGz in Mitochondrial Disease

Status Recruiting

Clinical Trial Summary

This is a multi-aim study, studying the effects of conventional exercise (measured through Cardiopulomary Exercises Testing or an in-bed pedal exercise) and passive exercise through periodic acceleration (pGz). Aim 1 will focus on the differences between primary mitochondrial disease (PMD) patients and healthy volunteers. Aim 2 is an exploratory aim, which will be studying the effects in patients admitted to the Children's Hospital of Philadelphia Pediatric Intensive Care Unit (PICU).

Clinical Trial Description

Aim 1: Primary Mitochondrial Disease Patients and Healthy Controls Individuals will be screened for eligibility for study entry, and answer questions relating to their ability to perform study procedures and their physical activity levels. Individuals who meet study criteria will have 3 study visits, and each study visit will involve a different intervention. At each of these study visits, individuals will complete one of the following interventions: Cardiopulmonary Exercise Testing (CPET), pGz administration through a bed or recliner, and pGz through a device called a Gentle Jogger. While participants will complete all three study visits, the order of the study visits will occur in random order. During the study visits, participants will have blood draws before and after the study intervention, a vascular ultrasound with a Lumason contrast agent before and after the study intervention, and a Creatine Chemical Exchange Saturation Transfer (CrCEST) MRI of the lower leg. Aim 2: Patients in the Pediatric Intensive Care Unit (PICU) Individuals will be screened for eligibility for study entry. Individuals who meet study criteria will have 2 study visits during their admission to the PICU. The first study visit will involve a pedal exercise and the second study visit will involve pGz administration through a device called a Gentle Jogger. During the study visits, participants will have blood draws before and after the study intervention, a vascular ultrasound with a Lumason contrast agent before and after the study intervention, and if able to safely complete, an CrCEST MRI of the lower leg. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05569122
Study type	Interventional
Source	Children's Hospital of Philadelphia
Contact	Katelynn Stanley, BS
Phone	215-426-0225
Email	stanleyk2@chop.edu
Status	Recruiting
Phase	Phase 1
Start date	March 22, 2023
Completion date	October 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03388528` - Low Residue Diet Study in Mitochondrial Disease	N/A
Completed	`NCT04378075` - A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy	Phase 2/Phase 3
Completed	`NCT03678740` - Diagnostic Odyssey Survey 2
Recruiting	`NCT06051448` - Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).	Phase 1/Phase 2
Completed	`NCT02909400` - The KHENERGY Study	Phase 2
Completed	`NCT02398201` - A Study of Bezafibrate in Mitochondrial Myopathy	Phase 2
Completed	`NCT03857880` - Identification of New Candidate Genes in Patients With Mitochondrial Disease by High Resolution Chromosome Analysis on DNA Chip
Not yet recruiting	`NCT06450964` - Establishment of Reproductive Cohort and Prediction Model of Genetic Counseling for Mitochondrial Genetic Diseases
Completed	`NCT04165239` - The KHENERGYZE Study	Phase 2
Completed	`NCT02284334` - Glycemic Index in Mitochondrial Disease
Recruiting	`NCT06080568` - Human Mitochondrial Stress-driven Obesity Resistance
Recruiting	`NCT06080581` - Mitochondrial Dysfunctions Driving Insulin Resistance
Recruiting	`NCT04802707` - Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome	Phase 2
Completed	`NCT04594590` - Natural History Study of SLC25A46 Mutation-related Mitochondriopathy
Completed	`NCT04580979` - Natural History Study of FDXR Mutation-related Mitochondriopathy
Withdrawn	`NCT03866954` - Trial of Erythrocyte Encapsulated Thymidine Phosphorylase In Mitochondrial Neurogastrointestinal Encephalomyopathy	Phase 2
Recruiting	`NCT04113447` - Mitochondrial Donation: An 18 Month Outcome Study.
Enrolling by invitation	`NCT04734626` - CrCest Study in Primary Mitochondrial Disease
Completed	`NCT03832218` - Executive Function Disorders and Anxio-depressive Symptomatology in Children and Adolescents With Mitochondrial Pathologies	N/A
Terminated	`NCT02473445` - A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.